CN Patent

CN1548436A — 新的2-烷基取代咪唑化合物

Assigned to SmithKline Beecham Corp · Expires 2004-11-24 · 21y expired

What this patent protects

本发明涉及用于治疗CSBP激酶介导的疾病的式(I)新的2－烷基取代咪唑化合物。

USPTO Abstract

本发明涉及用于治疗CSBP激酶介导的疾病的式(I)新的2－烷基取代咪唑化合物。

Drugs covered by this patent

nintedanib-esylate (NINTEDANIB ESYLATE)

Patent Metadata

Patent number: CN1548436A
Jurisdiction: CN
Classification: —
Expires: 2004-11-24
Drug substance claim: No
Drug product claim: No
Assignee: SmithKline Beecham Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.